These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27527810)

  • 1. Expression of several cytokines in prostate cancer: Correlation with clinical variables of patients. Relationship with biochemical progression of the malignance.
    Torrealba N; Rodríguez-Berriguete G; Fraile B; Olmedilla G; Martínez-Onsurbe P; Guil-Cid M; Paniagua R; Royuela M
    Cytokine; 2017 Jan; 89():105-115. PubMed ID: 27527810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer.
    Rodríguez-Berriguete G; Sánchez-Espiridión B; Cansino JR; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Fraile B; Royuela M
    Cytokine; 2013 Nov; 64(2):555-63. PubMed ID: 24063999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy.
    Rodríguez-Berriguete G; Torrealba N; Ortega MA; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Guil-Cid M; Fraile B; Royuela M
    BMC Cancer; 2015 Oct; 15():809. PubMed ID: 26507126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
    Torrealba N; Vera R; Fraile B; Martínez-Onsurbe P; Paniagua R; Royuela M
    Aging Male; 2020 Dec; 23(5):801-811. PubMed ID: 30973040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
    De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
    Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
    Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
    J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.
    Torrealba N; Rodriguez-Berriguete G; Fraile B; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Royuela M
    Aging Male; 2018 Sep; 21(3):211-222. PubMed ID: 29316844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Oncotarget; 2016 Oct; 7(41):67476-67484. PubMed ID: 27623212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
    Cohen BL; Gomez P; Omori Y; Duncan RC; Civantos F; Soloway MS; Lokeshwar VB; Lokeshwar BL
    Int J Cancer; 2006 Sep; 119(5):1082-7. PubMed ID: 16557596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
    Rabien A; Fritzsche FR; Jung M; Tölle A; Diamandis EP; Miller K; Jung K; Kristiansen G; Stephan C
    Int J Cancer; 2010 Nov; 127(10):2386-94. PubMed ID: 20473923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.